Pfizer gene therapy for bleeding disorder approved in Canada

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-04 06:21 GMT   |   Update On 2024-03-27 07:21 GMT
Advertisement

Canada: Pfizer said on Wednesday that Canada's health regulator approved its gene therapy for the treatment of a rare inherited bleeding disorder called hemophilia B ahead of a U.S. decision.

The approval was based on late-stage trials that showed a single dose of the therapy, to be sold under the brand name Beqvez, was superior to the current standard of care which involves replacing a blood-clotting protein called factor IX.

The U.S. Food and Drug Administration (FDA) had in November 2022 approved CSL's Hemgenix, making it the first one-time gene therapy for hemophilia B.

CSL had acquired exclusive global rights to Hemgenix from uniQure NV in 2021.

Pfizer is also seeking U.S. approval for its experimental antibody, marstacimab, to treat hemophilia A and B.

Hemophilia B is found in 1 in 40,000 people and represents about 15% of patients with hemophilia, according to the FDA.

The U.S. health regulator is expected to give its decision on Pfizer's therapy in the second quarter of 2024.

Original news source: https://www.reuters.com/business/healthcare-pharmaceuticals/canada-approves-pfizers-gene-therapy-bleeding-disorder-2024-01-03/ 

Read also: CDSCO panel Approves Pfizer's Protocol Amendment Proposal for Anti-cancer Drug Elranatamab




Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News